Other Lipid-Lowering Agents
Verified · Oct 2026Each drug acts at a different step of cholesterol and lipoprotein handling — absorption, synthesis, receptor recycling, VLDL output or lipoprotein assembly — and its adverse effects follow that step: flushing through a skin prostaglandin receptor (niacin), no muscle activation of a liver-only prodrug (bempedoic acid), and fat trapped in liver and gut (lomitapide).
Nursing view → administration, monitoring and patient teaching
Compare: Lipid-lowering agents compared →
Drugs
Mechanism
Ezetimibe inhibits the intestinal sterol transporter NPC1L1. Bempedoic acid, activated in the liver by ACSVL1, inhibits ATP-citrate lyase upstream of HMG-CoA reductase. Inclisiran, a GalNAc-conjugated siRNA, directs breakdown of PCSK9 mRNA in hepatocytes. Niacin partly inhibits adipose free-fatty-acid release and lowers hepatic VLDL synthesis. Icosapent ethyl (EPA) reduces hepatic VLDL-triglyceride synthesis and secretion. Lomitapide inhibits microsomal triglyceride transfer protein, blocking assembly of apo B lipoproteins. The first three raise hepatic LDL-receptor activity.
Ezetimibe: blocking cholesterol uptake at the brush border
Cholesterol comes from synthesis in the liver or absorption from the gut. Ezetimibe (a 2-azetidinone) inhibits the sterol transporter NPC1L1 at the small-intestine brush border; it neither increases bile-acid excretion nor inhibits hepatic synthesis. Less cholesterol reaches the liver, hepatic stores fall, and LDL receptors increase.
It is rapidly conjugated to an active glucuronide; multiple plasma peaks suggest enterohepatic recycling, and both forms have a half-life of about 22 hours. NPC1L1 also carries plant sterols, which is why ezetimibe treats homozygous sitosterolemia, and ezetimibe does not significantly affect fat-soluble vitamins.
Bempedoic acid: one step upstream of HMG-CoA reductase — in liver only
Acetyl-CoA, the building block of cholesterol, reaches the cytoplasm as citrate; ATP-citrate lyase (ACL) releases it. Bempedoic acid inhibits ACL, an enzyme upstream of HMG-CoA reductase, so less cholesterol is made and hepatic LDL receptors are upregulated.
It is a prodrug activated by ACSVL1, which is present predominantly in liver and absent from skeletal muscle, which helps minimize adverse muscle effects. Its other signature effect comes from the kidney: it inhibits the tubular transporter OAT2, raising uric acid.
Inclisiran: stopping PCSK9 before it is made
PCSK9 sends LDL receptors to degradation. The PCSK9 antibodies (separate page) bind PCSK9 and reduce free PCSK9 in the circulation; inclisiran works a step earlier. It is a double-stranded small interfering RNA conjugated to GalNAc, which targets it to hepatocytes, where the RNA-interference machinery directs catalytic breakdown of PCSK9 mRNA — more LDL receptors recycle to the cell surface.
Because the breakdown is catalytic, the effect far outlasts the drug: the plasma half-life is about 9 hours, yet LDL-C is still about 53% lower 180 days after a dose. That is why it is given at the start, at 3 months and then every 6 months.
Niacin: lipid effects, flushing and liver toxicity
Niacin’s lipid mechanism is not fully defined: it partly inhibits release of free fatty acids from adipose tissue, increases lipoprotein lipase activity and decreases hepatic VLDL and LDL synthesis.
Flushing — face, arms and chest, within about 30 minutes and gone after about an hour — comes from niacin acting on G-protein-coupled receptor 109A on epidermal Langerhans cells, which activates prostaglandins; aspirin taken beforehand can reduce it.
Two hepatic pathways explain the formulation rules: a high-capacity conjugation route (to nicotinuric acid) drives prostaglandin-mediated flushing, while a high-affinity route that is easily overwhelmed processes sustained-release forms and builds up liver-damaging products. Hence severe hepatotoxicity when sustained-release niacin replaces immediate-release at the same dose.
Icosapent ethyl: purified EPA
Icosapent ethyl is the ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. EPA reduces hepatic VLDL-triglyceride synthesis and/or secretion and speeds triglyceride clearance from VLDL — possibly through increased β-oxidation, inhibition of diacylglycerol acyltransferase (DGAT), decreased hepatic lipogenesis and increased lipoprotein lipase activity.
Its cardiovascular benefit is not fully explained: EPA is incorporated into carotid plaque, raises the EPA-to-arachidonic acid ratio and inhibits platelet aggregation under some ex vivo conditions.
Lomitapide: blocking the protein missing in abetalipoproteinemia
Microsomal triglyceride transfer protein (MTP), in the endoplasmic reticulum, mediates assembly of apo B-containing lipoproteins — chylomicrons in enterocytes and VLDL in hepatocytes. Lomitapide binds and inhibits MTP, so less VLDL is made and LDL-C falls; it is indicated for homozygous FH.
Inherited loss of MTP (MTTP mutations) causes abetalipoproteinemia: low or absent LDL and VLDL, fat malabsorption, fat-soluble vitamin (especially vitamin E) deficiency and acanthocytes. Lomitapide blocks the same step, and its gut effects echo the inherited disease — diarrhea and falling vitamin E and essential fatty acids, hence a low-fat diet and supplements — while fat retained in the liver causes steatosis and transaminase rises (the boxed warning).
Comparing the drugs
Target and signature effect
| Drug | Target | Main lipid effect | Signature problem |
|---|---|---|---|
| Ezetimibe | NPC1L1 (intestinal sterol uptake) | ↓ LDL-C | Myopathy and liver-enzyme rises, mainly with statins |
| Bempedoic acid | ATP-citrate lyase (liver-activated prodrug) | ↓ LDL-C | Hyperuricemia/gout (OAT2), tendon rupture |
| Inclisiran | PCSK9 mRNA (siRNA) | ↓ LDL-C (about 53% at day 180) | Injection-site reactions |
| Niacin | Adipose FFA release; hepatic VLDL synthesis | ↓ LDL-C and TG, ↑ HDL-C | Flushing (GPR109A → prostaglandins); hepatotoxicity |
| Icosapent ethyl | EPA: hepatic VLDL-TG output | ↓ TG | Atrial fibrillation, bleeding |
| Lomitapide | MTP (lipoprotein assembly) | ↓ LDL-C (HoFH) | Hepatic steatosis (boxed), diarrhea, ↓ vitamin E |
Pharmacokinetics at a glance
| Drug | Half-life | Clearance | Watch |
|---|---|---|---|
| Ezetimibe | About 22 h | Glucuronidated; enterohepatic recycling; feces and urine | Cyclosporine raises levels; bile-acid sequestrants lower them |
| Bempedoic acid | About 21 h | Glucuronides; renal | Raises simvastatin and pravastatin levels |
| Inclisiran | About 9 h (effect lasts months) | Nucleases | Effect is not tied to plasma levels |
| Lomitapide | About 40 h | Hepatic; CYP3A4 forms the major metabolites | Strong CYP3A4 inhibitors raise exposure about 27-fold |
Pharmacokinetics
- Ezetimibe: glucuronide and enterohepatic recycling — ezetimibe
- Ezetimibe is rapidly conjugated to ezetimibe-glucuronide (80–90% of drug in plasma), which is itself active; multiple plasma peaks suggest enterohepatic recycling, and both forms have a half-life of about 22 hours.
- Bempedoic acid: liver activation, renal elimination — bempedoic acid
- Absorption is unaffected by food; it is about 99% protein-bound, has a half-life of about 21 hours, and its glucuronides are eliminated mainly by the kidneys. Activation to the CoA form by ACSVL1 happens in liver, not muscle.
- Inclisiran: a short-lived drug with a long-lived effect — inclisiran
- Inclisiran has a plasma half-life of about 9 hours, does not accumulate, and is metabolized by nucleases; LDL-C falls within 14 days and is still about 53% lower at day 180.
- Lomitapide: extensive hepatic metabolism — lomitapide
- Lomitapide is 99.8% protein-bound and metabolized extensively by the liver — CYP3A4 forms its major metabolites, M1 and M3 — with a mean terminal half-life of about 40 hours.
- Lomitapide: CYP3A4-dependent — lomitapide
- A strong CYP3A4 inhibitor raised lomitapide exposure about 27-fold and weak inhibitors about 2-fold, so moderate and strong inhibitors are contraindicated; lomitapide in turn doubles simvastatin exposure and raises warfarin levels.
Pharmacogenomics
Uses & drug choice
- Ezetimibe to lower LDL-C in primary hyperlipidemia (with a statin or alone), in mixed hyperlipidemia with fenofibrate, in HoFH with other LDL-lowering therapy, and in homozygous sitosterolemia
- Bempedoic acid to reduce major cardiovascular events in adults unable to take recommended statin therapy, and to lower LDL-C in hypercholesterolemia including HeFH
- Inclisiran to lower LDL-C in adults with hypercholesterolemia and in patients 12 years and older with HeFH or HoFH
- Extended-release niacin to improve the lipid profile in primary hyperlipidemia and mixed dyslipidemia (lower LDL-C, apo B and triglycerides; higher HDL-C) and to reduce recurrent nonfatal MI after a prior MI
- Icosapent ethyl with a maximally tolerated statin to reduce cardiovascular events in adults with TG ≥ 150 mg/dL and established cardiovascular disease (or diabetes plus 2 more risk factors), and with diet for TG ≥ 500 mg/dL
- Lomitapide only for homozygous familial hypercholesterolemia (HoFH), with a low-fat diet and other LDL-lowering therapies
Adverse effects
- Flushing (niacin)
- Niacin activates G-protein-coupled receptor 109A on epidermal Langerhans cells, releasing vasodilating prostaglandins; aspirin beforehand blunts it.
- Hepatotoxicity with sustained-release niacin
- Sustained-release niacin goes down a high-affinity but easily overwhelmed hepatic pathway whose products accumulate and injure the liver, so swapping it for immediate-release at the same dose has caused severe hepatotoxicity.
- Hyperuricemia and gout (bempedoic acid)
- Bempedoic acid inhibits the renal tubular transporter OAT2, raising blood uric acid within weeks; it returns to baseline after stopping.
- Hepatic steatosis, diarrhea and low vitamin E (lomitapide)
- MTP inhibition stops apo B lipoprotein assembly, so fat stays in hepatocytes (steatosis, transaminase rises) and enterocytes (diarrhea, poor absorption of fat-soluble vitamins) — the gut features match abetalipoproteinemia.
- Bleeding (icosapent ethyl)
- EPA inhibits platelet aggregation under some ex vivo conditions, and bleeding was more frequent with aspirin, clopidogrel or warfarin.
- Fewer muscle effects (bempedoic acid)
- The activating enzyme ACSVL1 is absent from skeletal muscle, so the drug is not activated there.
Interactions
Contraindications
- Niacin with active liver disease or unexplained persistent transaminase elevations, active peptic ulcer disease, or arterial bleeding — Labeled contraindications for niacin.
- Lomitapide in pregnancy, with a moderate or strong CYP3A4 inhibitor, or with moderate or severe hepatic impairment or active liver disease — Labeled contraindications — fetal harm, a roughly 27-fold rise in lomitapide exposure with strong CYP3A4 inhibitors, and liver toxicity.
- Ezetimibe combined with a statin, fenofibrate or other LDL-lowering drug that is itself contraindicated — The combination takes on the partner drug’s contraindications.
- Bempedoic acid with a history of tendon disorders or tendon rupture use caution — Avoid — bempedoic acid increases the risk of tendon rupture.
- Ezetimibe with a fibrate other than fenofibrate use caution — Not recommended — both can increase cholesterol excretion into bile (gallstones).
High-yield
- Absorb — ezetimibe blocks NPC1L1 in the gut
- Build — bempedoic acid blocks ATP-citrate lyase, one step upstream of HMG-CoA reductase
- Recycle — inclisiran keeps LDL receptors recycling by silencing PCSK9
- Package — lomitapide blocks MTP, so VLDL and chylomicrons are not assembled
Niacin and icosapent ethyl sit apart: both cut hepatic VLDL-triglyceride output.
Practice questions
Q1A 54-year-old man starts extended-release niacin. Within 30 minutes of each dose his face and chest turn red and warm for about an hour.
What mediates this effect, and what blunts it?
- A.Histamine release from mast cells; blunted by antihistamines
- B.Prostaglandins released after GPR109A activation on epidermal Langerhans cells; blunted by aspirin beforehand
- C.Bradykinin accumulation; blunted by stopping ACE inhibitors
- D.Hepatotoxic metabolites; blunted by switching to sustained-release niacin
- E.IgE-mediated allergy; blunted by epinephrine
Show answer
B. Prostaglandins released after GPR109A activation on epidermal Langerhans cells; blunted by aspirin beforehand — Niacin acts on GPR109A on epidermal Langerhans cells, activating prostaglandins that vasodilate the skin; aspirin taken beforehand reduces flushing. Switching to sustained-release niacin at the same dose risks severe hepatotoxicity.
Q2A 61-year-old woman stopped two statins because of muscle pain. She is started on a drug that is a prodrug activated mainly in liver and that inhibits ATP-citrate lyase. Six weeks later her uric acid has risen.
Which drug is this, and why did uric acid rise?
- A.Ezetimibe — it blocks renal urate excretion through NPC1L1
- B.Niacin — it inhibits URAT1
- C.Bempedoic acid — it inhibits the renal tubular transporter OAT2
- D.Inclisiran — it causes tumor lysis
- E.Lomitapide — it causes hepatic urate overproduction
Show answer
C. Bempedoic acid — it inhibits the renal tubular transporter OAT2 — Bempedoic acid is activated by ACSVL1, present in liver but absent from muscle, and inhibits ACL. It inhibits renal OAT2, raising uric acid within the first weeks.
Q3A 24-year-old man with homozygous familial hypercholesterolemia is started on a drug available only through a REMS. Months later he has diarrhea, falling vitamin E levels and increased liver fat.
Which inherited disorder does this drug’s effect resemble?
- A.Familial chylomicronemia (lipoprotein lipase deficiency)
- B.Tangier disease
- C.Sitosterolemia
- D.Familial dysbetalipoproteinemia
- E.Abetalipoproteinemia (MTP deficiency)
Show answer
E. Abetalipoproteinemia (MTP deficiency) — Lomitapide inhibits microsomal triglyceride transfer protein, so apo B lipoproteins are not assembled — the defect of abetalipoproteinemia (MTTP mutations), with fat malabsorption and fat-soluble vitamin deficiency; in the liver the retained fat appears as steatosis.
Q4A patient asks why her new LDL-lowering injection, given in the clinic, is needed only twice a year even though the drug is undetectable in her blood within a day or two.
What explains the long duration?
- A.It is an siRNA that directs catalytic breakdown of PCSK9 mRNA inside hepatocytes
- B.It irreversibly inhibits HMG-CoA reductase
- C.It is a depot antibody released slowly from fat
- D.It permanently deletes the PCSK9 gene
- E.It binds circulating PCSK9 for months
Show answer
A. It is an siRNA that directs catalytic breakdown of PCSK9 mRNA inside hepatocytes — Inclisiran, GalNAc-targeted to hepatocytes, uses RNA interference to break down PCSK9 mRNA; with a plasma half-life of about 9 hours, LDL-C is still about 53% lower at day 180. The antibodies, by contrast, bind PCSK9 and reduce free PCSK9 in the circulation.
Sources
- Zetia (ezetimibe) — FDA label: NPC1L1 mechanism, indications, interactions — FDA / DailyMed
- Niacin extended-release tablets (Amneal) — FDA label: flushing, liver, glucose, substitution warning — FDA / DailyMed
- Niacor (niacin) — FDA label — FDA / DailyMed
- Nexletol (bempedoic acid) — FDA label: ACL inhibition, hyperuricemia, tendon rupture — FDA / DailyMed
- Leqvio (inclisiran) — FDA label: siRNA mechanism, administration — FDA / DailyMed
- Vascepa (icosapent ethyl) — FDA label: atrial fibrillation, bleeding, fish allergy — FDA / DailyMed
- Juxtapid (lomitapide) — FDA label: boxed hepatotoxicity, REMS, MTP mechanism, CYP3A4 — FDA / DailyMed
- The use of stems in the selection of INN (stems -imibe, -siran, -tapide) — World Health Organization
- Praluent (alirocumab) — FDA label: antibody binds PCSK9, reduces free PCSK9 (contrast with inclisiran) — FDA / DailyMed
- Ezetimibe — NPC1L1, glucuronide, enterohepatic recycling — StatPearls (NCBI)
- Bempedoic Acid — ATP-citrate lyase, ACSVL1 absent from muscle — StatPearls (NCBI)
- Niacin Toxicity — GPR109A flushing, hepatic pathways — StatPearls (NCBI)
- Abetalipoproteinemia — MTTP, MTP, fat-soluble vitamin deficiency — StatPearls (NCBI)
- Table of Pharmacogenomic Biomarkers in Drug Labeling — inclisiran, lomitapide (FH) — U.S. FDA
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.